[1] 肖兢,喻紫晨.肢体骨肉瘤合并病理性骨折的临床特点及相关影响因素[J].实用癌症杂志,2014,29(3):346-348. [2] 徐建立,张林,徐万鹏.骨肉瘤COSS–96方案综合治疗效果分析[J].中华肿瘤防治杂志,2013,20(8):622-624. [3] 牛晓辉,徐海荣.骨肉瘤的化疗进展[J].中国癌症志,2012,22(9):663-668. [4] 黄成校,郭卫春,郭哲.骨肉瘤的治疗进展[J].医学综述,2013,19( 11): 1979-1982. [5] MARDEKIAN S K,TULUC M.Malignant sarcomatous transformation of fibrous dysplasia[J].Head Neck Pathol,2015,9(1):100-103. [6] LO SCHIAVO A,RUOCCO E,RUSSO T,et al.Locus minoris resistentiae:An old but still valid way of thinking in medicine[J].Clin Dermatol,2014,32(5): 553-556. [7] LEE J A,PAIK E K,SEO J,et al.Radiotherapy and gemcitabine docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma[J]. J Clin Oncol,2016,46(2):138-143. [8] BERNTHAL N M,FEDERMAN N,EILBER F R,et al.Longterm results( >25 Years)of a randomized,prospective clinicaltrial evaluating chemotherapy in patients with high-grade,operable osteosarcoma[J]. Cancer,2012,118(23):5888-5893. [9] 陈丰,郭智,瞿嵘 .大剂量异环磷酰胺联合脂质体阿霉素治疗骨肉瘤的临床研究[J]. 实用癌症杂志,2015,30(5):676-678. [10] YANCEY A,HARRIS M S,EGBELAKIN A,et al.Risk factorsfor cisplatin associated ototoxicity in pediatric oncology patients[J]. Pediatr Blood Cancer,2012,59(1):144-148. [11] 张利恒,李亮,李晓峰,等.骨肉瘤化疗药物敏感性实验研究[J].中国实验诊断学,2013,17(1):100-102. [12] 徐明,许宋锋,于秀淳.骨肉瘤不含大剂量甲氨蝶呤新辅助化疗的疗效观察[J]. 中华肿瘤防治杂志,2015,22(2):138-142. [13] 黄飞,王显勋,罗小江.新辅助化疗结合保肢手术治疗骨肉瘤的临床研究[J].现代肿瘤医学,2015,23(13):1911-1913. |